Ensysce Biosciences (ENSCW) Non-Current Deferred Tax Liability (2018 - 2019)
Ensysce Biosciences (ENSCW) reported Non-Current Deferred Tax Liability of $8920.0 for Q3 2019, down 31.46% quarter-over-quarter from $13014.0 in Q2 2019.
Ensysce Biosciences (ENSCW) Non-Current Deferred Tax Liability (2018 - 2019) Analysis & Trends
Ensysce Biosciences (ENSCW) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $8920.0 in Q3 2019.
- Non-Current Deferred Tax Liability for Q3 2019 came in at $8920.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2019 was $8920.0 (changed N/A YoY), and the FY2018 annual result was $1764.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability slipped to $8920.0 in Q3 2019 per ENSCW's latest filing, from $13014.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $13014.0 in Q2 2019 and troughed at $1764.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ensysce Biosciences | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 8,920.00 |
| Sep 30, 2019 | 8,920.00 |
| Jun 30, 2019 | 13,014.00 |
| Jun 30, 2019 | 13,014.00 |
| Dec 31, 2018 | 1,764.00 |
| Dec 31, 2018 | 1,764.00 |